Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP) Academic Article Article uri icon


MeSH Major

  • Astrocytoma
  • Cerebral Ventricle Neoplasms
  • Endoscopy
  • Ependyma
  • Supratentorial Neoplasms
  • Tectum Mesencephali
  • Third Ventricle
  • Ventriculostomy


  • © 2020 British Society for Haematology and John Wiley & Sons Ltd Care of patients with chronic immune thrombocytopenia (ITP) who are refractory to available treatments can be quite challenging. Fostamatinib, an oral Syk inhibitor, is the newest FDA-approved agent for ITP. Phase 3 clinical trials demonstrated an overall response in 43% of patients treated with fostamatinib and use for two years has been reported. Herein, we report two patients with long histories of ITP without lasting responses to numerous first-, second- and third-line therapies with prolonged responses to ongoing fostamatinib. This shows that patients unresponsive to other agents may respond to fostamatinib and can have sustained benefit.

publication date

  • January 2020



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1111/bjh.16328

PubMed ID

  • 31900937